TY - JOUR
T1 - Intestinal microbiota mutualism and gastrointestinal diseases
AU - Leone, Angelo
AU - Tomasello, Giovanni
AU - Giammanco, Marco
AU - Di Majo, Danila
AU - Zeenny, Marie Noel
AU - Damiani, Provvidenza
AU - Zeenny, Marie-Noel
AU - Sinagra, Emanuele
AU - Sinagra, Emanuele
AU - Zein, Rosalyn Jurjus
AU - Tomasello, Giovanni
AU - Jurjus, Abdo
AU - Traina, Giovanna
AU - Damiani, Provvidenza
PY - 2015
Y1 - 2015
N2 - The purpose of this work is to investigate the link between an altered intestinal mcro-biota or dysbiosis and chronic inflammatory disorders, in particular inflammatory bowel disease (IBD). Along with probiotics, faecal microbiota transplantation (FMT) opts to be a promising therapeutic treatment for restoring the bacterial homeostasis of the hu-man intestine and reducing the risk of colorectal carcinogenesis. Microbiota is the com-plex microbial flora that resides in the gut establishing a mutually beneficial relation-ship. Alteration of the microbiota’s composition, termed as dysbiosis, may lead to pathological conditions. Treatment with probiotics can restore the normal commensal flora in IBD. Intestinal microbiota affects the circadian rhythm which in turn regulates the expression of different genes in GALT (gut associated lymphoid tissue) playing a role in the prevention of inflammation and colorectal cancer (CRC) progression. This article highlights the involvement of different microbial strains in the pathogenesis of dysbiosis and in the creation of a carcinogenic milieu caused by an altered stimulation of the immune system. Therapies targeting the equilibrium of the microbiota to switch off chronic inflammation and prevent the progression to CRC seem to be a promising therapeutic tool for a variety of inflammation-associated diseases.
AB - The purpose of this work is to investigate the link between an altered intestinal mcro-biota or dysbiosis and chronic inflammatory disorders, in particular inflammatory bowel disease (IBD). Along with probiotics, faecal microbiota transplantation (FMT) opts to be a promising therapeutic treatment for restoring the bacterial homeostasis of the hu-man intestine and reducing the risk of colorectal carcinogenesis. Microbiota is the com-plex microbial flora that resides in the gut establishing a mutually beneficial relation-ship. Alteration of the microbiota’s composition, termed as dysbiosis, may lead to pathological conditions. Treatment with probiotics can restore the normal commensal flora in IBD. Intestinal microbiota affects the circadian rhythm which in turn regulates the expression of different genes in GALT (gut associated lymphoid tissue) playing a role in the prevention of inflammation and colorectal cancer (CRC) progression. This article highlights the involvement of different microbial strains in the pathogenesis of dysbiosis and in the creation of a carcinogenic milieu caused by an altered stimulation of the immune system. Therapies targeting the equilibrium of the microbiota to switch off chronic inflammation and prevent the progression to CRC seem to be a promising therapeutic tool for a variety of inflammation-associated diseases.
UR - http://hdl.handle.net/10447/126140
UR - http://www.embj.org/images/ISSUE_2015/tomasello_1.pdf
M3 - Article
VL - 10
SP - 65
EP - 75
JO - EuroMediterranean Biomedical Journal
JF - EuroMediterranean Biomedical Journal
SN - 2279-7165
ER -